ERBB2 and metastatic neoplasm: In all, 144 (67.9%) patients of the “No HER2 therapy” group received chemotherapy with palliative intention before being enrolled in the study, 19 (9.0%) patients with metastatic disease had received only endocrine therapy, and 49 (23.1%) patients had not received any palliative therapy before enrollment (Table 2).